Molecular Dissection of Hyperdiploid Multiple Myeloma by Gene Expression Profiling
Top Cited Papers
- 1 April 2007
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 67 (7) , 2982-2989
- https://doi.org/10.1158/0008-5472.can-06-4046
Abstract
Hyperdiploid multiple myeloma (H-MM) is the most common form of myeloma. In this gene expression profiling study, we show that H-MM is defined by a protein biosynthesis signature that is primarily driven by a gene dosage mechanism as a result of trisomic chromosomes. Within H-MM, four independently validated patient clusters overexpressing nonoverlapping sets of genes that form cognate pathways/networks that have potential biological importance in multiple myeloma were identified. One prominent cluster, cluster 1, is characterized by high expression of cancer testis antigen and proliferation-associated genes. Tumors from these patients were more proliferative than tumors in other clusters (median plasma cell labeling index, 3.8; P < 0.05). Another cluster, cluster 3, is characterized by genes involved in tumor necrosis factor/nuclear factor-κB signaling and antiapoptosis. These patients have better response to bortezomib as compared with patients within other clusters (70% versus 29%; P = 0.02). Furthermore, for a group of patients generally thought to have better prognosis, a cluster of patients with short survival (cluster 1; median survival, 27 months) could be identified. This analysis illustrates the heterogeneity within H-MM and the importance of defining specific cytogenetic prognostic factors. Furthermore, the signatures that defined these clusters may provide a basis for tailoring treatment to individual patients. [Cancer Res 2007;67(7):2982–9]Keywords
All Related Versions
This publication has 37 references indexed in Scilit:
- The molecular classification of multiple myelomaBlood, 2006
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences, 2005
- Cyclin D dysregulation: an early and unifying pathogenic event in multiple myelomaBlood, 2005
- International Staging System for Multiple MyelomaJournal of Clinical Oncology, 2005
- NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responsesBlood, 2005
- Signaling control of mRNA translation in cancer pathogenesisOncogene, 2004
- Clinical and biologic implications of recurrent genomic aberrations in myelomaBlood, 2003
- Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myelomaBlood, 2002
- p16/INK4a gene inactivation by hypermethylation is associated with aggressive variants of monoclonal gammopathiesThe Hematology Journal, 2001
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONBritish Journal of Haematology, 1998